Your browser doesn't support javascript.
loading
The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results.
Terazawa, Tetsuji; Kato, Takeshi; Goto, Masahiro; Ohta, Katsuya; Satake, Hironaga; Noura, Shingo; Kagawa, Yoshinori; Kawakami, Hisato; Hasegawa, Hiroko; Yanagihara, Kazuhiro; Shingai, Tatsushi; Nakata, Ken; Kotaka, Masahito; Hiraki, Masayuki; Konishi, Ken; Nakae, Shiro; Sakai, Daisuke; Kurokawa, Yukinori; Shimokawa, Toshio; Tsujinaka, Toshimasa; Satoh, Taroh.
Afiliación
  • Terazawa T; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki-City, Japan.
  • Kato T; Department of Gastroenterological Surgery, National Hospital Organization Osaka National Hospital, Higashiosaka, Japan.
  • Goto M; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki-City, Japan.
  • Ohta K; Department of Gastroenterological Surgery, Higashiosaka City Medical Center, Osaka, Japan.
  • Satake H; Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Noura S; Department of Gastroenterological Surgery, Osaka Rosai Hospital, Sakai, Japan.
  • Kagawa Y; Department of Gastroenterological Surgery, Toyonaka Municipal Hospital, Toyonaka, Japan.
  • Kawakami H; Department of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
  • Hasegawa H; Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan.
  • Yanagihara K; Department of Gastroenterology and Hepatology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
  • Shingai T; Department of Medical Oncology, Kansai Electric Power Hospital, Osaka, Japan.
  • Nakata K; Department of Surgery, Saiseikai Senri Hospital, Suita, Japan.
  • Kotaka M; Department of Surgery, Sakai City Medical Center, Sakai, Japan.
  • Hiraki M; Gastrointestinal Cancer Center, Sano Hospital, Kobe, Japan.
  • Konishi K; Department of Surgery, Itami City Hospital, Itami, Japan.
  • Nakae S; Department of Surgery, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan.
  • Sakai D; Department of Medical Oncology, Mimihara General Hospital, Sakai, Japan.
  • Kurokawa Y; Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan.
  • Shimokawa T; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Tsujinaka T; Department of Medical Data Science, Graduate School of Medicine, Wakayama Medical University, Suita, Japan.
  • Satoh T; Cancer Center, Izumi City General Hospital, Izumi, Japan.
Oncologist ; 28(7): e565-e574, 2023 07 05.
Article en En | MEDLINE | ID: mdl-35947993
BACKGROUND: We previously reported the response rate of a phase II OGSG1602 study on panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer (CRC) [Terazawa T, Kato T, Goto M, et al. Oncologist. 2021;26(1):17]. Herein, we report a survival analysis. METHODS: Patients aged ≥65 years and considered unsuitable for intensive chemotherapy or aged ≥76 years were enrolled. Primary tumors located from the cecum to the transverse colon were considered right-sided tumors (RSTs); those located from the splenic flexure to the rectum were considered left-sided tumors (LSTs). RESULTS: Among the 36 enrolled patients, 34 were included in the efficacy analysis, with 26 and 8 having LSTs and RSTs, respectively. The median progression-free survival (PFS) and overall survival (OS) were 6.0 [95% CI, 5.4-10.0] and 17.5 months (95% CI, 13.8-24.3), respectively. Although no significant differences existed in PFS between patients with LST and RST {6.6 (95% CI, 5.4-11.5) vs. 4.9 months [95% CI, 1.9-not available (NA), P = .120]}, there were significant differences in OS [19.3 (95% CI, 14.2-NA) vs.12.3 months (95% CI, 9.9-NA), P = .043]. CONCLUSION: Panitumumab showed favorable OS in frail or elderly patients with RAS wild-type CRC and no prior exposure to chemotherapy. Panitumumab may be optimal for patients with LSTs (UMIN Clinical Trials Registry Number UMIN000024528).
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Anciano Frágil Límite: Aged / Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Anciano Frágil Límite: Aged / Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Japón
...